Frederick Wilhelm LombardJoseph Y. LoTanmay A. GokhaleJessie J MathersRu-Rong JiJeffrey N BrowndykeMichael C FosterNathan A BihlmeyerHoan T NgoScott RobertsonJonathan FooteMichael W ManningJohn W StaniferPakawat ChongsathidkietEric LippRoxanne J LarsenEric C. WestmanMohan MallipeddiDavid M HarlanNWORA LANCE OKEKERobert M TigheKaren ChiswellTakahiro SodaAuten RL JrJ Taylor HerbertR Clayton MusserKevin A FriedeAmanda E D Van SwearingenTyler J VovosKathryn S LytleGlenn M PremingerChristopher J HostlerChristopher J MacLellanChul Soo KimBradi B GrangerSicong LiuSeok-Yong LeeMichael StangKrista Rowe NicholsJon Andrews
P108
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in CancerAdvance Care Planning: Promoting Effective and Aligned Communication in the ElderlySafety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic MalignanciesSafety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric InpatientsSafety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)Safety and Efficacy of Tafamidis in Patients With Transthyretin CardiomyopathyA Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease PreventionBedside Optical Retinal Assessment of Hypoxic Ischemic Encephalopathy in InfantsCombining Objective and Subjective Sedation Assessment ToolsSafety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaSYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled HypertensionSurgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous IbuprofenSwitching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 InfectedIntegrated Health Services to Reduce Opioid Use While Managing Chronic PainRole of Social Incentives in PRO CollectionTolerance by Engaging Antigen During Cellular HomeostasisStudy to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
P6153
Q37838576-DBE576E9-4BB4-4ABA-BC27-BAB6DFEE03F0Q40600395-93DF5E55-8E19-449A-B738-C4510F0669A2Q41044434-DE07381B-F5CA-46A5-AE4B-6AE6EAA3FEB8Q41348143-A8E526A7-4052-4463-9737-315AF6790DB6Q42386007-67E54D8C-64D4-400B-93A7-2D8415139B34Q47228236-1AE03EAF-0AA8-4AC4-AD48-4AB0062731ECQ55172981-D47AE85B-6000-4CE0-A816-48B115E254C4Q56361976-043C488C-2AAA-4EF0-8DA0-C55C335D98BFQ56780604-8664D9B6-E9AD-4317-AE08-4D887A051899Q57428382-E7F9FBE4-8B1C-4034-B14B-33C051C3C024Q57441111-1A2EBD12-3302-49F8-80A3-D7168262FE0CQ57640325-736F821B-533C-4B10-AF5F-FD64E3DC55CDQ57902284-C77A3CD0-BB82-4A5B-B1EE-E0525B7EF424Q59123755-3FFAFD02-F50E-476B-A41C-2D5F9736CD3EQ59199758-7349B3F0-EE29-4076-A319-5CA6579045BDQ59676973-609BF0E3-470C-4C84-8F16-07497BB77979Q59750628-821DE3AE-6A82-4183-94DC-B9C1FC7C2A16Q59752533-B42A0F4F-7F29-421D-BF84-2191A163286DQ61093578-2B9CD183-F4B3-4433-BBCC-EC90AFE4F086Q62007927-1378B611-BC63-4AB6-ADC7-F15377EB99D1Q63386802-67BB52F1-12F2-43F4-8F21-97ED35B48948Q64683299-066DD83E-5EDD-429B-83B3-5637EB7FF01CQ64707931-5B5CEF75-C474-4343-A4B4-5E71CACC9D37Q68068606-E63476AB-ACD9-446B-A7AE-29F5D2CE198FQ73408566-786A0DD7-7F76-4B15-8C26-A230A4EF35C5Q79612795-60CFA33D-47E2-44F3-ABB8-C272BEDB1477Q82488755-2E33531D-1D4F-4DA2-8ABF-1A7631828F6AQ82488755-6D707754-1BD8-4AE1-B53F-FD61D6C7327BQ83462625-D4308F7B-7011-4A4D-A5D2-F31355D00EA5Q86078943-75517E5C-443B-4A83-82AE-68AE9385B002Q86704029-C5EA9722-A808-4101-9DD2-82C467E7B547Q86774164-62CB0504-10EF-4825-AC8F-FC8CD07B0457Q86818438-0B52FBE7-2179-42AF-AB48-BA6955CE1BECQ86972672-1FFEF50F-5D03-4928-9593-0B3C515CA897Q87216669-FA119BB2-0DFF-4273-AFFE-6E6824CE5EDFQ87466557-9B8AED95-6769-4465-AA5E-9D9C0CEC91FEQ87622493-D946BD9E-A8B5-4BD5-8906-06F70AE3CDA7Q87823095-CF44DD01-93EE-44DF-863B-10ED2AD2A127Q87834466-8DE87970-4AFA-4EAC-9A03-CDDA723FB1CCQ88101630-1C168FF4-C58C-45CC-9A54-38DAEA060EF1
P108
Q61862192-6BE3360B-778F-4B56-A581-8FC814EFB84EQ61906982-D4EB1BA9-ABB0-4836-AC9C-DE015403F380Q61909090-74C626BD-A70E-4B18-82AC-C786121D52E3Q61917821-5A93CC92-6AA6-4F77-9042-7FE67EA27AE0Q61969542-CCB5CDFA-6901-4C1B-BC3B-6EA36620F8FFQ61969733-382B746E-7B0D-4585-B06F-C07CFF315A35Q62025966-D0EB26B9-E3DB-4FF0-A042-84658432DE39Q62062941-EC7DDA6E-B4AE-4EAD-B7A9-0DF11287ADD1Q63063576-8C7AFA5D-4793-44DC-8B4E-532C36B937CCQ63229104-8C93B211-41D6-4327-8CA7-01054FF352E2Q63322688-244C3491-183E-48EE-9001-5319AB462595Q63336320-B3E24745-16AF-4A4E-8B67-76A9A97AA4DFQ63394791-EC5ADAE1-A5A5-4755-9C40-0170BC019D07Q63400512-B1EC5F2F-6570-47E1-B085-B700BBA92EBFQ63402252-528D7197-7A3B-486D-BE2B-22476A310597Q63571894-A282E860-5996-4930-922A-3D737142DFCEQ64140147-146256CD-F7E6-4207-A1BA-FE06C2F2501A
P6153
description
americká firma
@cs
bedrijf uit Verenigde Staten van Amerika
@nl
medical complex
@en
name
Duke University Health System
@en
Duke University Health System
@fr
杜克大学医学中心
@zh
type
label
Duke University Health System
@en
Duke University Health System
@fr
杜克大学医学中心
@zh
altLabel
Duke Health
@en
Duke Medicine
@en
Duke University Health Systems
@en
dukehealth.org
@en
dukemedicine.org
@en
prefLabel
Duke University Health System
@en
Duke University Health System
@fr
杜克大学医学中心
@zh
P355
P214
P244
P159
P213
0000 0001 0667 3730
P214
P2427
grid.412100.6
P244
n2001128286
P31
P3417
Duke-University-Health-System
P3500
P355
P373
Duke University
P571
1998-01-01T00:00:00Z
P6782
P7859
lccn-n2001128286